Guangdong JiAnTeBo Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a strategic partnership with Sanyou Biopharmaceuticals Co., Ltd. The collaboration aims to uncover new targets in metabolic diseases, including obesity, fatty liver, diabetes, and Alzheimer’s disease, with a focus on developing new pipelines of agonistic antibody drugs based on existing novel drug platforms. Financial details of the agreement were not disclosed.
JiAnTeBo, established in 2021, is dedicated to the development of innovative drugs for obesity and diabetes. Sanyou, founded in 2015, has developed a comprehensive 4C business model that encompasses differentiated Contract Research Organization (CRO) services, integrated Contract Development and Manufacturing Organization (CDO), collaborative Contract Production Organization (CPO), and distinctive Contract Research and Supply (CRS) solutions.
The partnership will capitalize on Sanyou’s robust antibody discovery platform, which includes screening over one trillion full human antibody library sub libraries, phage displayed mouse immune antibody libraries, and phage displayed alpaca immune antibody libraries. The collaboration will yield over 200 specific antibody drug lead molecules through a series of processes including antibody expression purification identification, affinity verification, and drug efficacy analysis. Additionally, JiAnTeBo’s comprehensive cell viability detection system will be utilized for functional testing, potentially paving new paths for the application of agonistic monoclonal antibodies in significant disease areas.- Flcube.com
